Phase I, Single-center, Inpatient, Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Oral Doses of AVL-3288 (Anvylic-3288) Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2017
At a glance
- Drugs AVL 3288 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Schizophrenia
- Focus Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 28 Dec 2016 Status changed from recruiting to discontinued.
- 15 Jun 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.